```html

Jerusalem Spotted Fever – A Comprehensive Medical Guide

Overview

Jerusalem spotted fever (JSF) is an acute, tick‑borne rickettsial disease caused by the bacterium Rickettsia conorii sub‑species israelensis. The infection is part of the Mediterranean spotted fever group and is most commonly reported in Israel, the West Bank, Jordan, and neighboring regions of the Middle East. Cases have also been identified in travelers returning from endemic areas.

Who it affects: The disease affects anyone bitten by an infected tick, but the highest incidence is among:

• Rural workers, shepherds, and farmers who have frequent contact with livestock or dogs.
• Military personnel and hikers who spend time in brushy or rocky terrain.
• Children playing outdoors in endemic regions.

Prevalence: Precise global numbers are limited because the disease is often under‑reported. The Israeli Ministry of Health estimates 30–50 confirmed cases per year, with occasional spikes during warm months (April–October). In a 2021 surveillance study, the incidence was ~1.2 cases per 100,000 people in endemic districts <sup>[1]</sup>. Travelers to the region have a reported infection rate of about 0.5 % when presenting with fever and rash after a tick bite.

Symptoms

Symptoms typically appear 5–10 days after the tick bite (incubation period). The classic triad—fever, headache, and a characteristic rash—may not be complete in every patient.

Early systemic signs

• Fever – sudden onset of high-grade (>38.5 °C) temperature.
• Severe headache – often described as “throbbing” and located at the forehead or temples.
• Myalgia – muscle aches, especially in the calves and lower back.
• Fatigue – profound tiredness that can limit daily activities.
• Gastrointestinal upset – nausea, occasional vomiting, or mild abdominal pain.

Dermatologic manifestations

• Eschar (tache noire) – a painless, dark necrotic ulcer at the tick bite site, often 0.5–2 cm in diameter. This is the most pathognomonic sign.
• Maculopapular rash – appears 2–5 days after fever, beginning on the wrists and ankles and spreading centripetally.
• Petechial or vesicular lesions – may co‑exist with the maculopapular rash, especially on the trunk.
• Palmar/plantar involvement – unlike many other rickettsioses, JSF frequently involves the palms and soles.

Later or severe manifestations

• Confusion or delirium (central nervous system involvement).
• Hepatomegaly and mild transaminitis.
• Renal dysfunction (elevated creatinine, hematuria).
• Respiratory distress in rare fulminant cases.

Causes and Risk Factors

JSF is caused by Rickettsia conorii sub‑species israelensis, an obligate intracellular gram‑negative bacterium that multiplies within endothelial cells lining small blood vessels. The organism is transmitted primarily by the bite of infected hard ticks (family Ixodidae), especially Rhipicephalus sanguineus (the brown dog tick) and Rhipicephalus turanicus.

Key risk factors

• Geographic exposure – living in or traveling to endemic Mediterranean‑Middle Eastern zones.
• Occupational exposure – farming, veterinary work, shepherding, or military service in rural areas.
• Outdoor recreation – hiking, camping, or picnicking in tick‑infested grass or scrub.
• Pet ownership – dogs can carry the brown dog tick; infested pets increase household exposure.
• Seasonality – tick activity peaks in spring and early autumn; most cases are reported between April and October.

Diagnosis

Prompt diagnosis is crucial because early antibiotic therapy dramatically reduces morbidity. Diagnosis relies on a combination of clinical suspicion, epidemiologic exposure, and laboratory testing.

Clinical assessment

• History of recent travel or residence in an endemic area.
• Recognition of the eschar and rash pattern.
• Exclusion of other febrile illnesses (e.g., meningococcemia, dengue, COVID‑19).

Laboratory tests

• Complete blood count (CBC) – may show mild leukocytosis or leukopenia; thrombocytopenia is common.
• Liver function tests (LFTs) – modest elevations in AST/ALT and alkaline phosphatase.
• Serology – indirect immunofluorescence assay (IFA) for IgM/IgG antibodies to Rickettsia conorii. A four‑fold rise in titer between acute and convalescent samples (taken 2–3 weeks apart) confirms infection.
• Polymerase chain reaction (PCR) – detection of rickettsial DNA from blood, eschar tissue, or skin biopsy. PCR offers rapid, specific confirmation (<90 % sensitivity) and is preferred when available.
• Western blot or micro-immunofluorescence – used in reference labs for ambiguous serology.

Imaging (if severe)

• Chest X‑ray – to assess for pulmonary infiltrates in cases with cough or dyspnea.
• Brain MRI/CT – reserved for patients with neurologic signs.

Treatment Options

Effective therapy is available, and most patients recover fully when treatment is started within the first 5 days of illness.

First‑line antibiotics

• Doxycycline – 100 mg orally twice daily for 7–10 days (or 200 mg daily in children >8 years). Doxycycline is the drug of choice for all ages, including pregnant women when benefits outweigh risks, per CDC guidelines <sup>[2]</sup>.
• Alternative agents (if doxycycline contraindicated):
  • Chloramphenicol 500 mg IV/PO every 6 h for 10 days.
  • Azithromycin 500 mg PO once daily for 5 days (limited data, used mainly in pediatric or pregnant cases).

Supportive care

• Antipyretics (acetaminophen or ibuprofen) for fever and headache.
• Adequate hydration—oral rehydration solutions or IV fluids if vomiting or hypotension.
• Monitoring of renal and hepatic function, especially in severe disease.

Hospitalization

Indicated for patients with any of the following:

• Severe rash covering >50 % of body surface.
• Neurologic involvement (confusion, seizures).
• Hypotension or signs of sepsis.
• Pregnant women or immunocompromised individuals.

Living with Jerusalem Spotted Fever

Most individuals recover without lasting effects, but the experience can be unsettling. Below are practical tips for patients who have been diagnosed.

Medication adherence

• Complete the full prescribed course of doxycycline even if symptoms improve within 2–3 days.
• Set reminders on your phone or use a pill‑box to avoid missed doses.

Symptom monitoring

• Track temperature twice daily; seek care if fever persists >48 h after starting antibiotics.
• Observe the eschar – it should crust and gradually shrink. Worsening redness, swelling, or drainage may signal secondary infection.

Activity & rest

• Take at least 5–7 days of relative rest; avoid strenuous exercise until you feel fully recovered.
• Return to work or school gradually – most patients are fit for normal activities after 10 days.

Psychological wellbeing

• Experiencing a high‑fever illness can cause anxiety. Discuss concerns with your clinician; many health systems offer short‑term counseling.
• Stay connected with family and friends to reduce isolation.

Prevention

Because JSF is tick‑borne, prevention focuses on minimizing tick exposure and promptly removing any attached ticks.

• Protective clothing – Wear long sleeves, long pants, and tuck pants into socks when in grass, shrubbery, or rocky areas.
• Tick repellents – Apply EPA‑registered repellents containing 20‑30 % DEET, picaridin, or IR3535 on skin; treat clothing with permethrin (0.5 % concentration).
• Pet care – Use veterinary‑approved tick collars or topical treatments on dogs; regularly inspect pets for ticks.
• Landscape management – Keep yards trimmed, remove leaf litter, and create tick‑free zones (e.g., gravel pathways) around homes.
• Tick checks – Conduct a full‑body inspection (including scalp and groin) within 24 hours after outdoor activities. Use fine‑tipped tweezers to grasp the tick close to the skin and pull straight upward.
• Vaccination – No human vaccine exists for JSF; research is ongoing.

Complications

When untreated or when therapy is delayed, JSF can lead to serious, occasionally life‑threatening complications.

• Vasculitis – Inflammation of small vessels can cause skin necrosis, gangrene, or ulceration.
• Neurologic sequelae – Encephalitis, meningitis, or cranial nerve palsies may result in persistent headaches or memory problems.
• Renal failure – Acute tubular necrosis requiring temporary dialysis.
• Hepatic dysfunction – Jaundice or prolonged elevation of liver enzymes lasting weeks.
• Respiratory distress – Acute respiratory distress syndrome (ARDS) reported in <1 % of severe cases.
• Mortality – Overall case‑fatality rate is low (<2 %) with appropriate treatment, but rises to 5–10 % in delayed or severe disease <sup>[3]</sup>.

When to Seek Emergency Care

References

1. Israeli Ministry of Health. “Annual Epidemiological Report – Rickettsial Diseases, 2022.” Available at: https://www.health.gov.il/Pages/default.aspx (accessed June 2026).
2. Centers for Disease Control and Prevention. “Rickettsial Diseases (Spotted Fever) – Treatment Guidelines.” Updated 2023. https://www.cdc.gov/rickettsia/treatment.html
3. Germain, P. et al. “Clinical outcomes of Mediterranean spotted fever and Jerusalem spotted fever: a retrospective cohort.” *Journal of Travel Medicine*, vol. 27, no. 3, 2021, pp. 1‑9.
4. Mayo Clinic. “Rickettsial diseases (spotted fevers) – Symptoms & Causes.” https://www.mayoclinic.org/diseases-conditions/spotted-fever
5. World Health Organization. “Rickettsial diseases: Global burden and control.” WHO Technical Report Series, No 1022, 2020.

```